Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases

Behavioural Brain Research

Volumn 312, Issue , 2016, Pages 415-430

  Sadek, Bassem ^a   Saad, Ali ^a   Sadeq, Adel ^b   Jalal, Fakhreya ^a   Stark, Holger ^c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b AL AIN UNIVERSITY   (United Arab Emirates)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Brain histamine receptors; Cognitive symptoms; H3R Antagonists; Histamine; Neuropsychiatric diseases

Indexed keywords

6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; A 431404; ABT 239; ABT 28; ABT 288; CIPROXIFAN; CLOBENPROPIT; DL 77; DONEPEZIL; GSK 239512; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTIDINE; IODOPHENPROPIT; IRDABISANT; JNJ 5207852; LEVETIRACETAM; METODICLOROFEN; MK 0249; MK 7288; OLANZAPINE; PF 03654746; PITOLISANT; PLACEBO; RISPERIDONE; SAR 110894; ST 1394; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIHISTAMINIC AGENT; HISTAMINE RECEPTOR;

ALLERGIC RHINITIS; ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; ATTENTION; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HISTAMINE RELEASE; HUMAN; HYPERALGESIA; IMPULSIVENESS; MEMORY DISORDER; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MULTIPLE SCLEROSIS; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SPATIAL MEMORY; WEIGHT GAIN; WORKING MEMORY; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; MEMORY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EPILEPSY; HISTAMINE ANTAGONISTS; HUMANS; MEMORY; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H3; SCHIZOPHRENIA;

EID: 84978737339     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.06.051     Document Type: Review

References (208)

1. [1] Kwiatkowski, H., Histamine in nervous tissue. J. Physiol. 102 (1943), 32–41.
2. [2] Haas, H.L., Sergeeva, O.A., Selbach, O., Histamine in the nervous system. Physiol. Rev. 88 (2008), 1183–1241.
3. [3] Garbarg, M., Barbin, G., Bischoff, S., Pollard, H., Schwartz, J.C., Dual localization of histamine in an ascending neuronal pathway and in non-neuronal cells evidenced by lesions in the lateral hypothalamic area. Brain Res. 106 (1976), 333–348.
4. [4] Schwartz, J.C., Barbin, G., Garbarg, B.M., Pollard, H., Rose, C., Verdiere, M., Neurochemical evidence for histamine acting as a transmitter in mammalian brain. Adv. Biochem. Psychopharmacol. 15 (1976), 111–126.
5. [5] Watanabe, T., Taguchi, Y., Hayashi, H., Tanaka, J., Shiosaka, S., Tohyama, M., et al. Evidence for the presence of a histaminergic neuron system in the rat brain: an immunohistochemical analysis. Neurosci. Lett. 39 (1983), 249–254.
6. [6] Panula, P., Yang, H.Y., Costa, E., Histamine-containing neurons in the rat hypothalamus. Proc. Natl. Acad. Sci. U. S. A. 81 (1984), 2572–2576.
7. [7] Verdiere, M., Rose, C., Schwartz, J.C., Synthesis and release of histamine studied on slices from rat hypothalamus. Eur. J. Pharmacol. 34 (1975), 157–168.
8. [8] Brown, R.E., Stevens, D.R., Haas, H.L., The physiology of brain histamine. Prog. Neurobiol. 63 (2001), 637–672.
9. [9] Blandina, P., Munari, L., Provensi, G., Passani, M.B., Histamine neurons in the tuberomamillary nucleus: a whole center or distinct subpopulations?. Front. Syst. Neurosci., 6, 2012, 33.
10. [10] Ericson, H., Watanabe, T., Kohler, C., Morphological analysis of the tuberomammillary nucleus in the rat brain: delineation of subgroups with antibody against L-histidine decarboxylase as a marker. J. Comp. Neurol. 263 (1987), 1–24.
11. [11] Prell, G.D., Hough, L.B., Khandelwal, J., Green, J.P., Lack of a precursor-product relationship between histamine and its metabolites in brain after histidine loading. J. Neurochem. 67 (1996), 1938–1944.
12. [12] Bongers, G., Bakker, R.A., Leurs, R., Molecular aspects of the histamine H3 receptor. Biochem. Pharmacol. 73 (2007), 1195–1204.
13. [13] Arrang, J.M., Garbarg, M., Schwartz, J.C., Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302 (1983), 832–837.
14. [14] Arrang, J.M., Garbarg, M., Schwartz, J.C., Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience 23 (1987), 149–157.
15. [15] Arrang, J.M., Garbarg, M., Schwartz, J.C., Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 15 (1985), 553–562.
16. [16] Arrang, J.M., Devaux, B., Chodkiewicz, J.P., Schwartz, J.C., H3-receptors control histamine release in human brain. J. Neurochem. 51 (1988), 105–108.
17. [17] Hill, S.J., Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 42 (1990), 45–83.
18. [18] Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., et al. International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49 (1997), 253–278.
19. [19] Lovenberg, T.W., Roland, B.L., Wilson, S.J., Jiang, X., Pyati, J., Huvar, A., et al. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 55 (1999), 1101–1107.
20. [20] Bakker, R.A., Wieland, K., Timmerman, H., Leurs, R., Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur. J. Pharmacol. 387 (2000), R5–7.
21. [21] Schneider, E.H., Seifert, R., The histamine H-receptor and the central and peripheral nervous system: a critical analysis of the literature. Neuropharmacology 106 (2015), 116–128.
22. [22] Sadek, B., Stark, H., Cherry-picked ligands at histamine receptor subtypes. Neuropharmacology 106 (2015), 56–73.
23. [23] Mobarakeh, J.I., Sakurada, S., Katsuyama, S., Kutsuwa, M., Kuramasu, A., Lin, Z.Y., et al. Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur. J. Pharmacol. 391 (2000), 81–89.
24. [24] Inoue, I., Yanai, K., Kitamura, D., Taniuchi, I., Kobayashi, T., Niimura, K., et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 13316–13320.
25. [25] Yanai, K., Son, L.Z., Endou, M., Sakurai, E., Nakagawasai, O., Tadano, T., et al. Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience 87 (1998), 479–487.
26. [26] Dai, H., Kaneko, K., Kato, H., Fujii, S., Jing, Y., Xu, A., et al. Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. Neurosci. Res. 57 (2007), 306–313.
27. [27] Dere, E., Zlomuzica, A., Viggiano, D., Ruocco, L.A., Watanabe, T., Sadile, A.G., et al. Episodic-like and procedural memory impairments in histamine H1 Receptor knockout mice coincide with changes in acetylcholine esterase activity in the hippocampus and dopamine turnover in the cerebellum. Neuroscience 157 (2008), 532–541.
28. [28] Schwartz, J.C., The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 163 (2011), 713–721.
29. [29] Hancock, A.A., Esbenshade, T.A., Krueger, K.M., Yao, B.B., Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci. 73 (2003), 3043–3072.
30. [30] Esbenshade, T.A., Browman, K.E., Bitner, R.S., Strakhova, M., Cowart, M.D., Brioni, J.D., The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol. 154 (2008), 1166–1181.
31. [31] Drutel, G., Peitsaro, N., Karlstedt, K., Wieland, K., Smit, M.J., Timmerman, H., et al. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol. Pharmacol. 59 (2001), 1–8.
32. [32] Liu, C., Ma, X., Jiang, X., Wilson, S.J., Hofstra, C.L., Blevitt, J., et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol. Pharmacol. 59 (2001), 420–426.
33. [33] Morse, K.L., Behan, J., Laz, T.M., West, R.E. Jr., Greenfeder, S.A., Anthes, J.C., et al. Cloning and characterization of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 296 (2001), 1058–1066.
34. [34] Zhu, Y., Michalovich, D., Wu, H., Tan, K.B., Dytko, G.M., Mannan, I.J., et al. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59 (2001), 434–441.
35. [35] Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark, H., et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408 (2000), 860–864.
36. [36] Sugimoto, Y., Iba, Y., Nakamura, Y., Kayasuga, R., Kamei, C., Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin. Exp. Allergy 34 (2004), 456–459.
37. [37] Hough, L.B., Rice, F.L., H3 receptors and pain modulation: peripheral, spinal, and brain interactions. J. Pharmacol. Exp. Ther. 336 (2011), 30–37.
38. [38] Ichinose, M., Belvisi, M.G., Barnes, P.J., Histamine H3-receptors inhibit neurogenic microvascular leakage in airways. J. Appl. Physiol. (1985) 68 (1990), 21–25.
39. [39] Imamura, M., Seyedi, N., Lander, H.M., Levi, R., Functional identification of histamine H3-receptors in the human heart. Circ. Res. 77 (1995), 206–210.
40. [40] Taylor, S.J., Kilpatrick, G.J., Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum. Br. J. Pharmacol. 105 (1992), 667–674.
41. [41] Martinez-Mir, M.I., Pollard, H., Moreau, J., Arrang, J.M., Ruat, M., Traiffort, E., et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 526 (1990), 322–327.
42. [42] Takeshita, Y., Watanabe, T., Sakata, T., Munakata, M., Ishibashi, H., Akaike, N., Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. Neuroscience 87 (1998), 797–805.
43. [43] Silver, R.B., Poonwasi, K.S., Seyedi, N., Wilson, S.J., Lovenberg, T.W., Levi, R., Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 501–506.
44. [44] Arrang, J.M., Morisset, S., Gbahou, F., Constitutive activity of the histamine H3 receptor. Trends Pharmacol. Sci. 28 (2007), 350–357.
45. [45] Gondard, E., Anaclet, C., Akaoka, H., Guo, R.X., Zhang, M., Buda, C., et al. Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology 38 (2013), 1015–1031.
46. [46] Toyota, H., Dugovic, C., Koehl, M., Laposky, A.D., Weber, C., Ngo, K., et al. Behavioral characterization of mice lacking histamine H(3) receptors. Mol. Pharmacol. 62 (2002), 389–397.
47. [47] Rizk, A., Curley, J., Robertson, J., Raber, J., Anxiety and cognition in histamine H3 receptor-/- mice. Eur. J. Neurosci. 19 (2004), 1992–1996.
48. [48] Lim, H.D., van Rijn, R.M., Ling, P., Bakker, R.A., Thurmond, R.L., Leurs, R., Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 314 (2005), 1310–1321.
49. [49] Zampeli, E., Tiligada, E., The role of histamine H4 receptor in immune and inflammatory disorders. Br. J. Pharmacol. 157 (2009), 24–33.
50. [50] Panula, P., Chazot, P.L., Cowart, M., Gutzmer, R., Leurs, R., Liu, W.L., et al. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol. Rev. 67 (2015), 601–655.
51. [51] Prast, H., Argyriou, A., Philippu, A., Histaminergic neurons facilitate social memory in rats. Brain Res. 734 (1996), 316–318.
52. [52] Malmberg-Aiello, P., Ipponi, A., Blandina, P., Bartolini, L., Schunack, W., Pro-cognitive effect of a selective histamine H1-receptor agonist, 2-(3-trifluoromethylphenyl)histamine, in the rat object recognition test. Inflamm. Res. 52:Suppl. 1 (2003), S33–4.
53. [53] Okamura, N., Yanai, K., Higuchi, M., Sakai, J., Iwata, R., Ido, T., et al. Functional neuroimaging of cognition impaired by a classical antihistamine, D-chlorpheniramine. Br. J. Pharmacol. 129 (2000), 115–123.
54. [54] Higuchi, M., Yanai, K., Okamura, N., Meguro, K., Arai, H., Itoh, M., et al. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99 (2000), 721–729.
55. [55] Panula, P., Rinne, J., Kuokkanen, K., Eriksson, K.S., Sallmen, T., Kalimo, H., et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82 (1998), 993–997.
56. [56] Mazurkiewicz-Kwilecki, I.M., Nsonwah, S., Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can. J. Physiol. Pharmacol. 67 (1989), 75–78.
57. [57] Medhurst, A.D., Atkins, A.R., Beresford, I.J., Brackenborough, K., Briggs, M.A., Calver, A.R., et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321 (2007), 1032–1045.
58. [58] Medhurst, A.D., Roberts, J.C., Lee, J., Chen, C.P., Brown, S.H., Roman, S., et al. Characterization of histamine H3 receptors in Alzheimer's disease brain and amyloid over-expressing TASTPM mice. Br. J. Pharmacol. 157 (2009), 130–138.
59. [59] Sheng, Y.L.J., Medhurst, A.D., Wilcock, G.K., Esiri, M., Wong, P.T., Chen, C.P., Lai, M.K., Preservation of cortical histamine H3 receptors in ischemic vascular and mixed dementias. J. Neurol. Sci., 2012, 110–114.
60. [60] Williams, R.H., Chee, M.J., Kroeger, D., Ferrari, L.L., Maratos-Flier, E., Scammell, T.E., et al. Optogenetic-mediated release of histamine reveals distal and autoregulatory mechanisms for controlling arousal. J. Neurosci. 34 (2014), 6023–6029.
61. [61] Schone, C., Apergis-Schoute, J., Sakurai, T., Adamantidis, A., Burdakov, D., Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons. Cell Rep. 7 (2014), 697–704.
62. [62] Nishino, S., Fujiki, N., Ripley, B., Sakurai, E., Kato, M., Watanabe, T., et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313 (2001), 125–128.
63. [63] Nishino, S., Sakurai, E., Nevsimalova, S., Yoshida, Y., Watanabe, T., Yanai, K., et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 32 (2009), 175–180.
64. [64] Parmentier, R., Anaclet, C., Guhennec, C., Brousseau, E., Bricout, D., Giboulot, T., et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem. Pharmacol. 73 (2007), 1157–1171.
65. [65] Parmentier, R., Ohtsu, H., Djebbara-Hannas, Z., Valatx, J.L., Watanabe, T., Lin, J.S., Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 22 (2002), 7695–7711.
66. [66] Lin, J.S., Sergeeva, O.A., Haas, H.L., Histamine H3 receptors and sleep-wake regulation. J. Pharmacol. Exp. Ther. 336 (2011), 17–23.
67. [67] Dauvilliers, Y., Bassetti, C., Lammers, G.J., Arnulf, I., Mayer, G., Rodenbeck, A., et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 12 (2013), 1068–1075.
68. [68] Fox, G.B., Esbenshade, T.A., Pan, J.B., Radek, R.J., Krueger, K.M., Yao, B.B., et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313 (2005), 176–190.
69. [69] Mochizuki, T., Okakura-Mochizuki, K., Horii, A., Yamamoto, Y., Yamatodani, A., Histaminergic modulation of hippocampal acetylcholine release in vivo. J. Neurochem. 62 (1994), 2275–2282.
70. [70] Komater, V.A., Browman, K.E., Curzon, P., Hancock, A.A., Decker, M.W., Fox, G.B., H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl.) 167 (2003), 363–372.
71. [71] Miyazaki, S., Imaizumi, M., Onodera, K., Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice. Methods Find. Exp. Clin. Pharmacol. 17 (1995), 653–658.
72. [72] Ligneau, X., Lin, J., Vanni-Mercier, G., Jouvet, M., Muir, J.L., Ganellin, C.R., et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J. Pharmacol. Exp. Ther. 287 (1998), 658–666.
73. [73] Stark, H., Sadek, B., Krause, M., Huls, A., Ligneau, X., Ganellin, C.R., et al. Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds. J. Med. Chem. 43 (2000), 3987–3994.
74. [74] Day, M., Pan, J.B., Buckley, M.J., Cronin, E., Hollingsworth, P.R., Hirst, W.D., et al. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem. Pharmacol. 73 (2007), 1123–1134.
75. [75] Komater, V.A., Buckley, M.J., Browman, K.E., Pan, J.B., Hancock, A.A., Decker, M.W., et al. Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav. Brain Res. 159 (2005), 295–300.
76. [76] Ding, F., Zheng, L., Liu, M., Chen, R., Leung, L.S., Ciproxifan, Luo T., An H3 receptor antagonist, improves short-term recognition memory impaired by isoflurane anesthesia. J. Anesth., 2016 [Epub ahead of print].
77. [77] Hancock, A.A., The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem. Pharmacol. 71 (2006), 1103–1113.
78. [78] Berlin, M., Boyce, C.W., Ruiz Mde, L., Histamine H3 receptor as a drug discovery target. J. Med. Chem. 54 (2011), 26–53.
79. [79] Cowart, M., Faghih, R., Curtis, M.P., Gfesser, G.A., Bennani, Y.L., Black, L.A., et al. 4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. 48 (2005), 38–55.
80. [80] Egan, M., Zhao, X., Gottwald, R., Harper-Mozley, L., Zhang, Y., Snavely, D., et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr. Res. 146 (2013), 224–230.
81. [81] Haig, G.M., Pritchett, Y., Meier, A., Othman, A.A., Hall, C., Gault, L.M., et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J. Alzheimers Dis. 42 (2014), 959–971.
82. [82] Othman, A.A., Haig, G., Florian, H., Locke, C., Gertsik, L., Dutta, S., The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers. Br. J. Clin. Pharmacol. 77 (2014), 965–974.
83. [83] Takano, T., Sakaue, Y., Sokoda, T., Sawai, C., Akabori, S., Maruo, Y., et al. Seizure susceptibility due to antihistamines in febrile seizures. Pediatr. Neurol. 42 (2010), 277–279.
84. [84] Paschou, P., Fernandez, T.V., Sharp, F., Heiman, G.A., Hoekstra, P.J., Genetic susceptibility and neurotransmitters in Tourette syndrome. Int. Rev. Neurobiol. 112 (2013), 155–177.
85. [85] Wei, Z., Wang, L., Zhang, M., Xuan, J., Wang, Y., Liu, B., et al. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J. Psychopharmacol. 26 (2012), 813–818.
86. [86] Guo, R.X., Anaclet, C., Roberts, J.C., Parmentier, R., Zhang, M., Guidon, G., et al. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice. Br. J. Pharmacol. 157 (2009), 104–117.
87. [87] McGaraughty, S., Chu, K.L., Cowart, M.D., Brioni, J.D., Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats. J. Pharmacol. Exp. Ther. 343 (2012), 13–20.
88. [88] Ashworth, S., Rabiner, E.A., Gunn, R.N., Plisson, C., Wilson, A.A., Comley, R.A., et al. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J. Nucl. Med. 51 (2010), 1021–1029.
89. [89] Wilson, D.M., Apps, J., Bailey, N., Bamford, M.J., Beresford, I.J., Brackenborough, K., et al. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 23 (2013), 6890–6896.
90. [90] Wilson, D.M., Apps, J., Bailey, N., Bamford, M.J., Beresford, I.J., Briggs, M.A., et al. The discovery of the benzazepine class of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 23 (2013), 6897–6901.
91. [91] Holtz, N.A., Anker, J.J., Regier, P.S., Claxton, A., Carroll, M.E., Cocaine self-administration punished by i.v. histamine in rat models of high and low drug abuse vulnerability: effects of saccharin preference, impulsivity, and sex. Physiol. Behav. 122 (2013), 32–38.
92. [92] Grove, R.A., Harrington, C.M., Mahler, A., Beresford, I., Maruff, P., Lowy, M.T., et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr. Alzheimer Res. 11 (2014), 47–58.
93. [93] Nathan, P.J., Boardley, R., Scott, N., Berges, A., Maruff, P., Sivananthan, T., et al. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H(3) receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr. Alzheimer Res. 10 (2013), 240–251.
94. [94] Raddatz, R., Hudkins, R.L., Mathiasen, J.R., Gruner, J.A., Flood, D.G., Aimone, L.D., et al. CEP-26401 (irdabisant), a potent and selective histamine H(3) receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J. Pharmacol. Exp. Ther. 340 (2012), 124–133.
95. [95] Hudkins, R.L., Becknell, N.C., Lyons, J.A., Aimone, L.D., Olsen, M., Haltiwanger, R.C., et al. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity. Eur. J. Med. Chem. 95 (2015), 349–356.
96. [96] Hudkins, R.L., Raddatz, R., Tao, M., Mathiasen, J.R., Aimone, L.D., Becknell, N.C., et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J. Med. Chem. 54 (2011), 4781–4792.
97. [97] Ligneau, X., Perrin, D., Landais, L., Camelin, J.C., Calmels, T.P., Berrebi-Bertrand, I., et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. 320 (2007), 365–375.
98. [98] Lin, J.S., Dauvilliers, Y., Arnulf, I., Bastuji, H., Anaclet, C., Parmentier, R., et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol. Dis. 30 (2008), 74–83.
99. [99] Meier, G., Apelt, J., Reichert, U., Grassmann, S., Ligneau, X., Elz, S., et al. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists. Eur. J. Pharm. Sci. 13 (2001), 249–259.
100. [100] Swanson, D.M., Shah, C.R., Lord, B., Morton, K., Dvorak, L.K., Mazur, C., et al. Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists. Eur. J. Med. Chem. 44 (2009), 4413–4425.
101. [101] Brioni, J.D., Esbenshade, T.A., Garrison, T.R., Bitner, S.R., Cowart, M.D., Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J. Pharmacol. Exp. Ther. 336 (2011), 38–46.
102. [102] Nikolic, K., Filipic, S., Agbaba, D., Stark, H., Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities. CNS Neurosci. Ther. 20 (2014), 613–623.
103. [103] Kasteleijn-Nolst Trenite, D., Parain, D., Genton, P., Masnou, P., Schwartz, J.C., Hirsch, E., Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Epilepsy Behav. 28 (2013), 66–70.
104. [104] Sadek, B., Saad, A., Subramanian, D., Shafiullah, M., Lazewska, D., Kiec-Kononowiczc, K., Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult rats. Neuropharmacology 106 (2015), 46–55.
105. [105] Griebel, G., Pichat, P., Pruniaux, M.P., Beeske, S., Lopez-Grancha, M., Genet, E., et al. SAR110894, a potent histamine H(3)-receptor antagonist, displays procognitive effects in rodents. Pharmacol. Biochem. Behav. 102 (2012), 203–214.
106. [106] Inocente, C., Arnulf, I., Bastuji, H., Thibault-Stoll, A., Raoux, A., Reimao, R., et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin. Neuropharmacol. 35 (2012), 55–60.
107. [107] Sun, H., MacLeod, C., Mostoller, K., Mahon, C., Han, L., Renger, J.J., et al. Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. J. Clin. Pharmacol. 53 (2013), 1294–1302.
108. [108] Kukko-Lukjanov, T.K., Soini, S., Taira, T., Michelsen, K.A., Panula, P., Holopainen, I.E., Histaminergic neurons protect the developing hippocampus from kainic acid-induced neuronal damage in an organotypic coculture system. J. Neurosci. 26 (2006), 1088–1097.
109. [109] Bhowmik, M., Saini, N., Vohora, D., Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res. 1581 (2014), 129–140.
110. [110] Canonaco, M., Madeo, M., Alo, R., Giusi, G., Granata, T., Carelli, A., et al. The histaminergic signaling system exerts a neuroprotective role against neurodegenerative-induced processes in the hamster. J. Pharmacol. Exp. Ther. 315 (2005), 188–195.
111. [111] Jia, F., Kato, M., Dai, H., Xu, A., Okuda, T., Sakurai, E., et al. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology 50 (2006), 404–411.
112. [112] Elger, C.E., Helmstaedter, C., Kurthen, M., Chronic epilepsy and cognition. Lancet Neurol. 3 (2004), 663–672.
113. [113] Seeman, P., Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4 (2010), 56–73.
114. [114] Baronio, D., Gonchoroski, T., Castro, K., Zanatta, G., Gottfried, C., Riesgo, R., Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann. Gen. Psychiatry, 13, 2014, 34.
115. [115] Bishara, D., Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 6 (2010), 561–572.
116. [116] Bondy, B., Spellmann, I., Pharmacogenetics of antipsychotics: useful for the clinician. Curr. Opin. Psychiatry 20 (2007), 126–130.
117. [117] Lewis, D.A., Levitt, P., Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25 (2002), 409–432.
118. [118] von Coburg, Y., Kottke, T., Weizel, L., Ligneau, X., Stark, H., Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg. Med. Chem. Lett. 19 (2009), 538–542.
119. [119] Witkin, J.M., Nelson, D.L., Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther. 103 (2004), 1–20.
120. [120] Browman, K.E., Komater, V.A., Curzon, P., Rueter, L.E., Hancock, A.A., Decker, M.W., et al. Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav. Brain Res. 153 (2004), 69–76.
121. [121] Brown, J.W., Whitehead, C.A., Basso, A.M., Rueter, L.E., Zhang, M., Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int. J. Neuropsychopharmacol. 16 (2013), 889–904.
122. [122] Mahmood, D., Khanam, R., Pillai, K.K., Akhtar, M., Reversal of oxidative stress by histamine H(3) receptor-ligands in experimental models of schizophrenia. Arzneimittelforschung 62 (2012), 222–229.
123. [123] Wong, M.M., Chen, E.Y., Lui, S.S., Tso, S., Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin. Schizophr. Relat. Psychoses 5 (2011), 135–141.
124. [124] Bardgett, M.E., Davis, N.N., Schultheis, P.J., Griffith, M.S., Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 95 (2011), 64–72.
125. [125] Coruzzi, G., Pozzoli, C., Adami, M., Grandi, D., Guido, N., Smits, R., et al. Strain-dependent effects of the histamine H(4) receptor antagonist JNJ7777120 in a murine model of acute skin inflammation. Exp. Dermatol. 21 (2012), 32–37.
126. [126] Hsieh, G.C., Chandran, P., Salyers, A.K., Pai, M., Zhu, C.Z., Wensink, E.J., et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol. Biochem. Behav. 95 (2010), 41–50.
127. [127] Fisher, R.S., van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia 46 (2005), 470–472.
128. [128] Stephen, L.J., Brodie, M.J., Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 25 (2011), 89–107.
129. [129] Loscher, W., Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol. Sci. 23 (2002), 113–118.
130. [130] Meldrum, B.S., Neurotransmission in epilepsy. Epilepsia 36:Suppl. 1 (1995), S30–5.
131. [131] Kamei, C., Involvement of central histamine in amygdaloid kindled seizures in rats. Behav. Brain Res. 124 (2001), 243–250.
132. [132] Kamei, C., Ishizawa, K., Kakinoki, H., Fukunaga, M., Histaminergic mechanisms in amygdaloid-kindled seizures in rats. Epilepsy Res. 30 (1998), 187–194.
133. [133] Kamei, C., Ohuchi, M., Sugimoto, Y., Okuma, C., Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats. Brain Res. 887 (2000), 183–186.
134. [134] Bhowmik, M., Khanam, R., Vohora, D., Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives. Br. J. Pharmacol. 167 (2012), 1398–1414.
135. [135] Tuomisto, L., Tacke, U., Is histamine an anticonvulsive inhibitory transmitter. Neuropharmacology 25 (1986), 955–958.
136. [136] Kakinoki, H., Ishizawa, K., Fukunaga, M., Fujii, Y., Kamei, C., The effects of histamine H3-receptor antagonists on amygdaloid kindled seizures in rats. Brain Res. Bull. 46 (1998), 461–465.
137. [137] Onodera, K., Tuomisto, L., Tacke, U., Airaksinen, M., Strain differences in regional brain histamine levels between genetically epilepsy-prone and resistant rats. Methods Find. Exp. Clin. Pharmacol. 14 (1992), 13–16.
138. [138] Yawata, I., Tanaka, K., Nakagawa, Y., Watanabe, Y., Murashima, Y.L., Nakano, K., Role of histaminergic neurons in development of epileptic seizures in EL mice. Brain Res. Mol. Brain Res. 132 (2004), 13–17.
139. [139] Zhang, L.S., Chen, Z., Huang, Y.W., Hu, W.W., Wei, E.Q., Yanai, K., Effects of endogenous histamine on seizure development of pentylenetetrazole-induced kindling in rats. Pharmacology 69 (2003), 27–32.
140. [140] Hirai, T., Okuma, C., Harada, C., Mio, M., Ohtsu, H., Watanabe, T., et al. Development of amygdaloid kindling in histidine decarboxylase-deficient and histamine H1 receptor-deficient mice. Epilepsia 45 (2004), 309–313.
141. [141] Yokoyama, H., Sato, M., Iinuma, K., Onodera, K., Watanabe, T., Centrally acting histamine H1 antagonists promote the development of amygdala kindling in rats. Neurosci. Lett. 217 (1996), 194–196.
142. [142] Yokoyama, H., Onodera, K., Iinuma, K., Watanabe, T., 2-Thiazolylethylamine, a selective histamine H1 agonist, decreases seizure susceptibility in mice. Pharmacol. Biochem. Behav. 47 (1994), 503–507.
143. [143] Chen, Z., Li, Z., Sakurai, E., Izadi Mobarakeh, J., Ohtsu, H., Watanabe, T., et al. Chemical kindling induced by pentylenetetrazol in histamine H(1) receptor gene knockout mice (H(1)KO), histidine decarboxylase-deficient mice (HDC(-/-)) and mast cell-deficient W/W(v) mice. Brain Res. 968 (2003), 162–166.
144. [144] Kiviranta, T., Tuomisto, L., Airaksinen, E.M., Histamine in cerebrospinal fluid of children with febrile convulsions. Epilepsia 36 (1995), 276–280.
145. [145] Miyata, I., Saegusa, H., Sakurai, M., Seizure-modifying potential of histamine H1 antagonists: a clinical observation. Pediatr. Int. 53 (2011), 706–708.
146. [146] Tuomisto, L., Lozeva, V., Valjakka, A., Lecklin, A., Modifying effects of histamine on circadian rhythms and neuronal excitability. Behav. Brain Res. 124 (2001), 129–135.
147. [147] Brigo, F., Ausserer, H., Tezzon, F., Nardone, R., When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav. 27 (2013), 439–442.
148. [148] Schmidt, D., The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. 50 (2002), 21–32.
149. [149] Hermann, B., Meador, K.J., Gaillard, W.D., Cramer, J.A., Cognition across the lifespan: antiepileptic drugs, epilepsy, or both. Epilepsy Behav. 17 (2010), 1–5.
150. [150] Zhang, L., Chen, Z., Ren, K., Leurs, R., Chen, J., Zhang, W., et al. Effects of clobenpropit on pentylenetetrazole-kindled seizures in rats. Eur. J. Pharmacol. 482 (2003), 169–175.
151. [151] Sadek, B., Kuder, K., Subramanian, D., Shafiullah, M., Stark, H., Lazewska, D., et al. Anticonvulsive effect of nonimidazole histamine H3 receptor antagonists. Behav. Pharmacol. 25 (2014), 245–252.
152. [152] Ishizawa, K., Chen, Z., Okuma, C., Sugimoto, Y., Fujii, Y., Kamei, C., Participation of GABAergic and histaminergic systems in inhibiting amygdaloid kindled seizures. Jpn. J. Pharmacol. 82 (2000), 48–53.
153. [153] Yokoyama, H., Onodera, K., Iinuma, K., Watanabe, T., Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice. Eur. J. Pharmacol. 234 (1993), 129–133.
154. [154] Vohora, D., Pal, S.N., Pillai, K.K., Thioperamide, a selective histamine H3 receptor antagonist, protects against PTZ-induced seizures in mice. Life Sci. 66 (2000), PL297–301.
155. [155] Hansen, K.B., Mullasseril, P., Dawit, S., Kurtkaya, N.L., Yuan, H., Vance, K.M., et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J. Pharmacol. Exp. Ther. 333 (2010), 650–662.
156. [156] Dai, H., Fu, Q., Shen, Y., Hu, W., Zhang, Z., Timmerman, H., et al. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur. J. Pharmacol. 563 (2007), 117–123.
157. [157] Sadek, B., Schwed, J.S., Subramanian, D., Weizel, L., Walter, M., Adem, A., et al. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties. Eur. J. Med. Chem. 77 (2014), 269–279.
158. [158] Yuen, E.S., Sims, J.R., How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy. Seizure 23 (2014), 490–493.
159. [159] Aldenkamp, A.P., Alpherts, W.C., The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 47 (2006), 1153–1159.
160. [160] Pahuja, M., Mehla, J., Reeta, K.H., Tripathi, M., Gupta, Y.K., Effect of Anacyclus pyrethrum on pentylenetetrazole-induced kindling, spatial memory, oxidative stress and rho-kinase II expression in mice. Neurochem. Res. 38 (2013), 547–556.
161. [161] Visweswari, G., Prasad, K.S., Chetan, P.S., Lokanatha, V., Rajendra, W., Evaluation of the anticonvulsant effect of Centella asiatica (gotu kola) in pentylenetetrazol-induced seizures with respect to cholinergic neurotransmission. Epilepsy Behav. 17 (2010), 332–335.
162. [162] Chin, J., Scharfman, H.E., Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. Epilepsy Behav. 26 (2013), 343–351.
163. [163] Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007), 697–711.
164. [164] Minkeviciene, R., Rheims, S., Dobszay, M.B., Zilberter, M., Hartikainen, J., Fulop, L., et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 29 (2009), 3453–3462.
165. [165] Scharfman, H.E., Alzheimer's disease and epilepsy: insight from animal models. Future Neurol. 7 (2012), 177–192.
166. [166] Scharfman, H.E., Untangling Alzheimer's disease and epilepsy. Epilepsy Curr. 12 (2012), 178–183.
167. [167] Kleen, J.K., Scott, R.C., Holmes, G.L., Lenck-Santini, P.P., Hippocampal interictal spikes disrupt cognition in rats. Ann. Neurol. 67 (2010), 250–257.
168. [168] Kleen, J.K., Scott, R.C., Lenck-Santini, P.P., Holmes, G.L., Cognitive and behavioral co-morbidities of epilepsy. Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W., Delgado-Escueta, A.V., (eds.) Jasper's Basic Mechanisms of the Epilepsies, 2012, National Center for Biotechnology Information (US), Bethesda (MD).
169. [169] Sendrowski, K., Sobaniec, W., Stasiak-Barmuta, A., Sobaniec, P., Popko, J., Study of the protective effects of nootropic agents against neuronal damage induced by amyloid-beta (fragment 25–35) in cultured hippocampal neurons. Pharmacol. Rep.: PR 67 (2015), 326–331.
170. [170] Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31 (2011), 700–711.
171. [171] Sanchez, P.E., Zhu, L., Verret, L., Vossel, K.A., Orr, A.G., Cirrito, J.R., et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2895–903.
172. [172] Vohora, D., Pal, S.N., Pillai, K.K., Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy. Pharmacol. Biochem. Behav. 68 (2001), 735–741.
173. [173] Chen, G.L., Wang, W., Xu, Z.H., Zhu, B., Wang, L.S., Zhou, G., et al. Genotype-phenotype correlation for histamine N-methyltransferase in a Chinese Han population. Clin. Chim. Acta 334 (2003), 179–183.
174. [174] Preuss, C.V., Wood, T.C., Szumlanski, C.L., Raftogianis, R.B., Otterness, D.M., Girard, B., et al. Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol. Pharmacol. 53 (1998), 708–717.
175. [175] Micallef, S., Stark, H., Sasse, A., Polymorphisms and genetic linkage of histamine receptors. Life Sci. 93 (2013), 487–494.
176. [176] Yang, X., Liu, C., Zhang, J., Han, H., Wang, X., Liu, Z., et al. Association of histamine N-methyltransferase Thr105Ile polymorphism with Parkinson's disease and schizophrenia in Han Chinese: a case-control study. PLoS One., 10, 2015, e0119692.
177. [177] Rojano, E., Ranea, J.A., Perkins, J.R., Characterisation of non-coding genetic variation in histamine receptors using AnNCR-SNP. Amino Acids, 2016 [Epub ahead of print].
178. [178] Esbenshade, T.A., Browman, K.E., Miller, T.R., Krueger, K.M., Komater-Roderwald, V., Zhang, M., et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 343 (2012), 233–245.
179. [179] Strasser, A., Buschauer, A., Histamine receptors. Pharmakon 2 (2015), 109–116.
180. [180] Chen, Z., Kamei, C., Facilitating effects of histamine on spatial memory deficit induced by scopolamine in rats. Acta Pharmacol. Sin. 21 (2000), 814–818.
181. [181] Huang, Y.W., Chen, Z., Hu, W.W., Zhang, L.S., Wu, W., Ying, L.Y., et al. Facilitating effect of histamine on spatial memory deficits induced by dizocilpine as evaluated by 8-arm radial maze in SD rats. Acta Pharmacol. Sin. 24 (2003), 1270–1276.
182. [182] de Almeida, M.A., Izquierdo, I., Memory facilitation by histamine. Arch. Int. Pharmacodyn. Ther. 283 (1986), 193–198.
183. [183] Li, Q., Jin, C.L., Xu, L.S., Zhu-Ge, Z.B., Yang, L.X., Liu, L.Y., et al. Histidine enhances carbamazepine action against seizures and improves spatial memory deficits induced by chronic transauricular kindling in rats. Acta Pharmacol. Sin. 26 (2005), 1297–1302.
184. [184] Yu, C., Shen, Y., Xu, L., Zhu, Y., Zhuge, Z., Huang, Y., et al. Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats. Physiol. Behav. 87:4 (2006), 687–693 PP:687–93.
185. [185] Chen, Z., Sugimoto, Y., Kamei, C., Effects of intracerebroventricular injection of alpha-fluoromethylhistidine on radial maze performance in rats. Pharmacol. Biochem. Behav. 64 (1999), 513–518.
186. [186] Kamei, C., Tasaka, K., Effect of histamine on memory retrieval in old rats. Biol. Pharm. Bull. 16 (1993), 128–132.
187. [187] Sakai, N., Sakurai, E., Sakurai, E., Yanai, K., Mirua, Y., Watanabe, T., Depletion of brain histamine induced by alpha-fluoromethylhistidine enhances radial maze performance in rats with modulation of brain amino acid levels. Life Sci. 62 (1998), 989–994.
188. [188] Blandina, P., Giorgetti, M., Bartolini, L., Cecchi, M., Timmerman, H., Leurs, R., et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br. J. Pharmacol. 119 (1996), 1656–1664.
189. [189] Rubio, S., Begega, A., Santin, L.J., Miranda, R., Arias, J.L., Effects of histamine precursor and (R)-alpha-methylhistamine on the avoidance response in rats. Behav. Brain Res. 124 (2001), 177–181.
190. [190] Huang, Y.W., Hu, W.W., Chen, Z., Zhang, L.S., Shen, H.Q., Timmerman, H., et al. Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague-Dawley rats. Behav. Brain Res. 151 (2004), 287–293.
191. [191] Benetti, F., Baldi, E., Bucherelli, C., Blandina, P., Passani, M.B., Histaminergic ligands injected into the nucleus basalis magnocellularis differentially affect fear conditioning consolidation. Int. J. Neuropsychopharmacol. 16 (2013), 575–582.
192. [192] Orsetti, M., Ferretti, C., Gamalero, R., Ghi, P., Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory. Psychopharmacology (Berl.) 159 (2002), 133–137.
193. [193] Charlier, Y., Brabant, C., Serrano, M.E., Lamberty, Y., Tirelli, E., The prototypical histamine H3 receptor inverse agonist thioperamide improves multiple aspects of memory processing in an inhibitory avoidance task. Behav. Brain Res. 253 (2013), 121–127.
194. [194] Bernaerts, P., Lamberty, Y., Tirelli, E., Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behav. Brain Res. 154 (2004), 211–219.
195. [195] Pascoli, V., Boer-Saccomani, C., Hermant, J.F., H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology (Berl.) 202 (2009), 141–152.
196. [196] Trofimiuk, E., Braszko, J.J., Single dose of H3 receptor antagonist–ciproxifan–abolishes negative effects of chronic stress on cognitive processes in rats. Psychopharmacology (Berl.) 231 (2014), 209–219.
197. [197] Bardgett, M.E., Davis, N.N., Schultheis, P.J., Griffith, M.S., Ciproxifan an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 95 (2010), 64–72.
198. [198] Foley, A.G., Prendergast, A., Barry, C., Scully, D., Upton, N., Medhurst, A.D., et al. H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms. Neuropsychopharmacology 34 (2009), 2585–25600.
199. [199] Brabant, C., Charlier, Y., Tirelli, E., The histamine H(3)-receptor inverse agonist pitolisant improves fear memory in mice. Behav. Brain Res. 243 (2013), 199–204.
200. [200] Kamei, C., Okuma, C., [Role of central histamine in amygdaloid kindled seizures]. Nihon Yakurigaku Zasshi 117 (2001), 329–334.
201. [201] Yokoyama, H., Onodera, K., Maeyama, K., Sakurai, E., Iinuma, K., Leurs, R., et al. Clobenpropit (VUF-9153), a new histamine H3 receptor antagonist, inhibits electrically induced convulsions in mice. Eur. J. Pharmacol. 260 (1994), 23–28.
202. [202] Sturman, G., Freeman, P., Histaminergic modulation and chemically-induced seizures in mice. Agents Actions 36 (1992), 358–360.
203. [203] Chen, Z., Li, W.D., Zhu, L.J., Shen, Y.J., Wei, E.Q., Effects of histidine, a precursor of histamine, on pentylenetetrazole-induced seizures in rats. Acta Pharmacol. Sin. 23 (2002), 361–366.
204. [204] Vinogradova, L.V., Shatskova, A.B., Tuomisto, L., Histaminergic modulation of acoustically induced running behavior in rats. Brain Res. 1148 (2007), 198–204.
205. [205] Yokoyama, H., Onodera, K., Maeyama, K., Yanai, K., Iinuma, K., Tuomisto, L., et al. Histamine levels and clonic convulsions of electrically-induced seizure in mice: the effects of alpha-fluoromethylhistidine and metoprine. Naunyn. Schmiedebergs Arch. Pharmacol. 346 (1992), 40–45.
206. [206] Ago, J., Ishikawa, T., Matsumoto, N., Ashequr Rahman, M., Kamei, C., Mechanism of imipramine-induced seizures in amygdala-kindled rats. Epilepsy Res. 72 (2006), 1–9.
207. [207] Vohora, D., Saraogi, P., Yazdani, M.A., Bhowmik, M., Khanam, R., Pillai, K.K., Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc.) 46 (2010), 265–277.
208. [208] Harada, C., Hirai, T., Fujii, Y., Harusawa, S., Kurihara, T., Kamei, C., Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia. Methods Find. Exp. Clin. Pharmacol. 26 (2004), 263–270.